Abstract 4564
Background
The current standard-of-care first-line therapy for patients (pts) with recurrent/metastatic cervical cancer (r/mCC) is paclitaxel/platinum ± bevacizumab (BEV). However, approximately 50% of pts who are eligible to receive this regimen do not respond to the treatment. Tissue factor (TF) is highly expressed in cervical cancer and is associated with poor prognosis. Tisotumab vedotin (TV) is an investigational first-in-class antibody-drug conjugate comprising a fully human monoclonal antibody targeting TF conjugated to the microtubule-disrupting agent monomethyl auristatin E via a protease-cleavable linker. Single-agent TV demonstrated encouraging antitumor activity (independent review committee–assessed confirmed ORR, 22%; median DOR, 6.0 mo) and a manageable safety profile in pts with previously treated r/mCC. innovaTV 205/ENGOT-cx8 (NCT03786081; GOG-3024) is a global, multicenter, open-label, phase 1/2 trial evaluating the safety and antitumor activity of TV in combination with BEV, pembrolizumab (PEM), or carboplatin (CBP) in pts with untreated and previously treated r/mCC. Results from the innovaTV 205 study will inform the further clinical development of TV in cervical cancer.
Trial design
Approximately 140 adult pts with recurrent or stage IVB squamous, adenosquamous, or adenocarcinoma of the cervix; measurable disease; and ECOG PS 0-1 will be enrolled. The phase 1 portion of the study will consist of 3 dose escalation cohorts for identification of the recommended phase 2 dose (RP2D) of TV with BEV, PEM, or CBP. The phase 2 portion will include 3 expansion cohorts. In the dose escalation cohorts, previously treated pts will receive escalating doses of TV (IV 1Q3W) in combination with escalating doses of BEV (IV 1Q3W), a fixed dose of PEM (IV 1Q3W), or a fixed dose of CBP (IV 1Q3W). In the expansion cohorts, pts who have not received prior systemic therapy for r/mCC will receive 1) TV RP2D + PEM or 2) TV RP2D + CBP; pts who received 1-2 prior treatments for r/mCC will receive TV RP2D + PEM. Additional cohorts might be added. The primary endpoint of phase 2 is ORR (RECIST v1.1). Secondary endpoints include DOR, time to response, PFS, OS, and safety.
Clinical trial identification
NCT03786081; GOG-3024.
Editorial acknowledgement
ApotheCom, San Francisco, CA, USA.
Legal entity responsible for the study
Genmab.
Funding
Genmab.
Disclosure
I.B. Vergote: Advisory / Consultancy: Advaxis; Advisory / Consultancy: Eisai; Advisory / Consultancy: MSD Belgium; Advisory / Consultancy: Roche NV; Advisory / Consultancy, Research grant / Funding (self): Genmab; Advisory / Consultancy: F. Hoffmann-La Roche; Advisory / Consultancy, Travel / Accommodation / Expenses: PharmaMar; Advisory / Consultancy: Millennium; Advisory / Consultancy: Clovis; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy, Travel / Accommodation / Expenses: Tesaro; Advisory / Consultancy, Research grant / Funding (self): Oncoinvent; Advisory / Consultancy: Immunogen; Research grant / Funding (self): Amgen; Research grant / Funding (self), Travel / Accommodation / Expenses: Roche; Research grant / Funding (self): Stichting Tegen Kanker; Travel / Accommodation / Expenses: Takeda. N. Concin: Advisory / Consultancy: Seattle Genetics; Advisory / Consultancy: AstraZeneca; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Genmab; Travel / Accommodation / Expenses: Amgen. M.R. Mirza: Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self): Biocad; Honoraria (self), Research grant / Funding (institution): Clovis; Honoraria (self): Geneos; Honoraria (self): Genmab; Honoraria (self): Karyopharm; Honoraria (self): Merck; Honoraria (self): Oncology Venture; Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self): Seattle Genetics; Honoraria (self): Sera Prognostics; Honoraria (self): Sotio; Honoraria (self), Research grant / Funding (institution): Tesaro; Honoraria (self): ZaiLab; Research grant / Funding (institution): Boehringer Ingelheim. A. Malmberg: Full / Part-time employment: Genmab. L. Eaton: Full / Part-time employment: Genmab. L. Nicacio: Full / Part-time employment: Seattle Genetics. D. Lorusso: Advisory / Consultancy, Research grant / Funding (institution): Tesaro; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy, Research grant / Funding (institution): Clovis; Advisory / Consultancy: Merrimack. I. Soumaoro: Full / Part-time employment: Genmab. B.J. Monk: Honoraria (self), Advisory / Consultancy, Oncomed (honoraria/consultant): AbbVie; Honoraria (institution), Advisory / Consultancy, Oncoquest (honoraria/consultant): Advaxis; Honoraria (self), Advisory / Consultancy, Oncosec (honoraria/consultant): Agenus; Honoraria (self), Advisory / Consultancy, Perthera (honoraria/consultant): Amgen; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Pfizer (honoraria/consultant): AstraZeneca; Honoraria (self), Advisory / Consultancy, Precision Oncology (honoraria/consultant): ChemoCare; Honoraria (self), Advisory / Consultancy, Puma (honoraria/consultant): ChemoID; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Roche/Genentech (honoraria/speaker/consultant): Clovis; Honoraria (self), Advisory / Consultancy, Samumed (honoraria/consultant): Conjupro; Honoraria (self), Advisory / Consultancy, Takeda (honoraria/consultant): Eisai; Honoraria (self), Advisory / Consultancy, Vesaro (honoraria/speaker/consultant): Geistlich; Honoraria (self), Advisory / Consultancy, VBL (honoraria/consultant): Genmab; Honoraria (self), Advisory / Consultancy: ImmunoGen; Honoraria (self), Advisory / Consultancy: Immunomedics; Honoraria (self), Advisory / Consultancy: Incyte; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Janssen/J&J; Honoraria (self), Advisory / Consultancy: Mateon (formerly Oxigene); Honoraria (self), Advisory / Consultancy: Merck; Advisory / Consultancy: Myriad; Honoraria (self), Advisory / Consultancy: Nucana. D.M. O’Malley: Advisory / Consultancy, Research grant / Funding (institution), Officer / Board of Directors, Ergomed Clinical Research (research support - institution): Clovis; Advisory / Consultancy, Research grant / Funding (institution), Exelixis (research support - institution): AstraZeneca; Advisory / Consultancy, Henry Jackson Foundation (research support - institution): Janssen; Advisory / Consultancy, Research grant / Funding (institution), Genentech (research support - institution): Gynecologic Oncology Group; Advisory / Consultancy, GSK (research support - institution): Myriad; Advisory / Consultancy, Research grant / Funding (institution), INC Research (research support - institution): Tesaro; Advisory / Consultancy, inVentiv Health Clinical (research support - institution): Novocure; Advisory / Consultancy, Janssen Research and Development (research support - institution): Translational Genomics/Cordgenics; Officer / Board of Directors, Ludwig Institute for Cancer Research (research support - institution): Novocure; Officer / Board of Directors, Novartis (research support - institution): Amgen; Research grant / Funding (institution), Officer / Board of Directors, PharmaMar (research support - institution): Immunogen; Advisory / Consultancy, Research grant / Funding (institution), Pfizer (research support - institution): AbbVie; Advisory / Consultancy, PRA International (research support - institution): Health Analytics; Advisory / Consultancy, Regeneron (research support - institution): Ambry; Research grant / Funding (institution), Sanofi (research support - institution): Advaxis; Research grant / Funding (institution), Serono (research support - institution): Agenus; Research grant / Funding (institution), Stemcentrx (research support - institution): Ajinomoto; Research grant / Funding (institution), Tracon (research support - institution): Array BioPharma; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Eisai.
Resources from the same session
3278 - Immune-Related Gene Expression Profiling after Neoadjuvant Chemotherapy (NACT) of Ovarian High-Grade Serous Carcinoma
Presenter: Luis Manso
Session: Poster Display session 2
Resources:
Abstract
4906 - Tumor-infiltrating lymphocytes (TILs) in patients with epithelial ovarian cancer undergoing neoadjuvant chemotherapy: A restrospective study
Presenter: Sara Giovannoni
Session: Poster Display session 2
Resources:
Abstract
3919 - Prognostic significance of elements of the adaptive immunity in the microenvironment of epithelial ovarian cancer.
Presenter: Periklis Foukas
Session: Poster Display session 2
Resources:
Abstract
5139 - Neutrophil-to-lymphocyte ratio predicts platinum sensitivity in epithelial ovarian cancer patients: a MITO24 retrospective study
Presenter: Alberto Farolfi
Session: Poster Display session 2
Resources:
Abstract
4212 - The prognostic impact of monocyte to lymphocyte ratio (MLR) in advanced epithelial ovarian cancer (EOC)
Presenter: Marc Cucurull Salamero
Session: Poster Display session 2
Resources:
Abstract
5123 - TP53 Hotspot mutations as immunoreactive neoantigens define a signature with differential survival outcomes in advanced ovarian cancer
Presenter: Marica Garziera
Session: Poster Display session 2
Resources:
Abstract
3795 - Use of bevacizumab (Bev) in real life for first-line (fl) treatment of ovarian cancer (OC)/ The GINECO ENCOURAGE cohort of 500 French patients
Presenter: Dominique Berton-Rigaud
Session: Poster Display session 2
Resources:
Abstract
2359 - Phase II study: Letrozole maintenance therapy after first line chemotherapy in patients with advanced serous and endometrioid ovarian cancer
Presenter: Alexandra Tyulyandina
Session: Poster Display session 2
Resources:
Abstract
3619 - Baseline IPI (Immune Prognostic Index) predicts survival in patients with advanced cervical cancer treated with immune checkpoint inhibitors (ICI).
Presenter: Felix Blanc-Durand
Session: Poster Display session 2
Resources:
Abstract
3474 - Preselecting tumor-infiltrating lymphocyte subsets to implement adoptive inmmunotherapy in ovarian cancer
Presenter: Diego Salas-Benito
Session: Poster Display session 2
Resources:
Abstract